A study which tested the immune response of COPD patients to COVID-19 vaccination has shown they respond in a similar way to healthy people.

On Sunday May 8th MEU took part in the Manchester Charity Dragon Boat Challenge at Sale Water Park. MEU successfully raised over £500 for Manchester Young Lives.

EpiEndo Pharmaceuticals, the clinical-stage biopharmaceutical company developing disease-modifying therapeutics for chronic respiratory disorders, has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.

We’re delighted to support our local volunteer blood bike service, Blood Bikes Manchester with our recent donation of £2,000. We believe that this is an invaluable resource to society and we aim to help the charity where we can. To date, we have raised £7,000 for this worthy cause!

Our Directors of Operations, David Rogers, was one of a few guests selected to personally meet HRH The Prince of Wales at a reception held for the 2020 and 2021 winners of the Queen’s Award for Enterprise at Windsor Castle on Wednesday, 10th November.

The Medicines Evaluation Unit Ltd (MEU) has been awarded the Queen’s Award for Enterprise: International Trade for its outstanding growth in overseas sales over the last three years.  Now in [ … ]

We were delighted to present The North West Lung Centre Charity with a cheque for £500,000 this week.

This means that to date, we have donated over £10 million to the charity, which directly supports lung research and patient care in the North West.

We are delighted to be collaborating with Reykjavik-based EpiEndo Pharmaceuticals on its First-in-Human Clinical trial of its Lead Compound, EP395, for Chronic Inflammatory Airway Disease.

The trial is led by our Medical Director, Professor Dave Singh, Professor of Respiratory Pharmacology at the University of Manchester.

The Medicines Evaluation Unit was a major participating centre in a study with Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases.

This week, Verona has announced positive Phase 2 data with a pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe COPD for this study.

The initiation of the Phase 2 study in patients in the United Kingdom (UK) follows the successful completion of dosing in the Phase 1 study in healthy volunteers at the same clinical unit in the UK, allowing for a rapid transition to Phase 2.